Hematology outcomes for patients treated with ivosidenib + azacitidine or placebo + azacitidine in the ITT population. Mean ± standard error hemoglobin (A), platelet counts (B), and neutrophil counts (C) over time. BL, baseline; C1D8, cycle 1 day 8.